{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T18:57:12Z","timestamp":1776538632585,"version":"3.51.2"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>We described the Memorial Sloan Kettering Cancer Center New York IIB (MSK-NYII) protocol pilot in 1993, for the treatment of acute lymphoblastic leukemia (ALL) in children at high risk of early relapse. We now report MSK-NYII for the treatment of T-ALL\/T-lymphoma over a 15-year period. A review of all patient charts identified 63 treated from 1\/1\/2000-12\/31\/2015, with a median follow-up of 9.9 years. Further follow-ups were confounded by the COVID pandemic. Remissions (CR) were defined as &lt;5% marrow blast count on Day 28 and resolution of extramedullary disease. Forty-four had T-ALL, and 19 had stage III\/IV lymphoblastic lymphoma (T-LL). Median age at diagnosis was 13.6 years (range 0.4 to 23.7). At diagnosis central nervous system (CNS) leukemia was present in 7\/63 patients (11%), cranial nerve palsy in 3 (5%), CNS2 [&lt;5cells\/\u00b5L cerebrospinal fluid with blasts seen on cytospin] in 11 (17%), testicular enlargement in 3 (5%), and mediastinal mass in 45 (71%). On Day 8, 37 T-ALL (86%) were rapid early responders with &lt;25% marrow blasts. 54 patients had an examination, cerebrospinal fluid, and marrow evaluation on day 28. Remission was demonstrated in 53 (98%) after prior marrow and CNS disease. The 19 T-lymphoma patients had no evidence of disease on day 28. Four relapses in marrow were recorded during therapy. Second remissions were able to be achieved. One patient died without having relapsed and is counted as an event in the event-free survival (EFS) analysis. Four patients, including 3 after the second CR transplant, died during follow-up. One unusual case of T-ALL recurred as T-LL of the colon 5.5 years after diagnosis, 3.5 years after therapy discontinuation. Fifteen years after diagnosis 88% (95% CI=78%-98%) survived event-free, and 91% (95% CI=82%-100%) survived. Twenty-five patients received irradiation. Three had RT to the testes, 3 had cranial RT for cranial nerve palsies, and 19 had cranial radiation for either CNS leukemia, CNS2, or for initial white blood cell &gt;100,000\/\u00a0\u00b5L. The MSK-NYIIB protocol, with a 94% 5-year and 88% 15-year EFS, is an effective therapy for the treatment of T-ALL\/lymphoma, with similar toxicity to other high-risk regimens.<\/jats:p>","DOI":"10.1097\/mph.0000000000002999","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T20:00:11Z","timestamp":1738612811000},"page":"59-66","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of T-cell Leukemia\/Lymphoma in Children and Young Adults With the Memorial Sloan Kettering Cancer Center New York IIB Protocol"],"prefix":"10.1097","volume":"47","author":[{"given":"Peter G.","family":"Steinherz","sequence":"first","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[{"name":"Biostatistics and Epidemiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Suser","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Forlenza","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neerav","family":"Shukla","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Trippett","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Wolden","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel","family":"Steinherz","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2008-1033805","article-title":"Acute lymphoblastic leukemia therapy study BFM 79\/81 in children and adolescents: intensified reinduction therapy for patients with different risk for relapse","volume":"194","author":"Henze","year":"1982","journal-title":"Klin Padiatr"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.1986.4.5.744","article-title":"Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group","volume":"4","author":"Steinherz","year":"1986","journal-title":"J Clin Oncol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00043426-198821000-00009","article-title":"Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children\u2019s Cancer Study Group Study CCG-193P","volume":"10","author":"Gaynon","year":"1988","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(88)92596-2","article-title":"Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group","volume":"2","author":"Gaynon","year":"1988","journal-title":"Lancet"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.1993.11.11.2234","article-title":"Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106","volume":"11","author":"Gaynon","year":"1993","journal-title":"J Clin Oncol"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1996.14.2.389","article-title":"Cytoreduction and prognosis in acute lymphoblastic leukemia\u2014the importance of early marrow response: report from the Childrens Cancer Group","volume":"14","author":"Steinherz","year":"1996","journal-title":"J Clin Oncol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4","article-title":"Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children\u2019s Cancer Group","volume":"82","author":"Steinherz","year":"1998","journal-title":"Cancer"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0889-8588(18)30640-3","article-title":"Acute lymphoblastic leukemia of childhood","volume":"1","author":"Steinherz","year":"1987","journal-title":"Hematol Oncol Clin North Am"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.1996.14.1.18","article-title":"Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia","volume":"14","author":"Smith","year":"1996","journal-title":"J Clin Oncol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0025-7125(16)32504-4","article-title":"Changing concepts of treatment in acute leukemia","volume":"55","author":"Clarkson","year":"1971","journal-title":"Med Clin North Am"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/1097-0142(197406)33:6<1491::AID-CNCR2820330604>3.0.CO;2-#","article-title":"Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol)","volume":"33","author":"Haghbin","year":"1974","journal-title":"Cancer"},{"key":"R15-20250527","first-page":"337","article-title":"Non-Hodgkin\u2019s lymphoma in children: results of treatment with LSA2-L2 protocol","volume":"2","author":"Wollner","year":"1975","journal-title":"Br J Cancer Suppl"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/cncr.11615","article-title":"Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center","volume":"98","author":"Mora","year":"2003","journal-title":"Cancer"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion","volume":"96","author":"Legha","year":"1982","journal-title":"Ann Intern Med"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","article-title":"Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation","volume":"65","author":"Shapira","year":"1990","journal-title":"Cancer"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1097-0142(19910915)68:6<1221::AID-CNCR2820680607>3.0.CO;2-R","article-title":"A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors","volume":"68","author":"Casper","year":"1991","journal-title":"Cancer"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1002\/1097-0142(19931115)72:10<3120::AID-CNCR2820721038>3.0.CO;2-Q","article-title":"Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol","volume":"72","author":"Steinherz","year":"1993","journal-title":"Cancer"},{"key":"R23-20250527","first-page":"735","article-title":"Biology and treatment of childhood T-lineage acute lymphoblastic leukemia","volume":"91","author":"Uckun","year":"1998","journal-title":"Blood"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol"},{"key":"R25-20250527","first-page":"431","article-title":"Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules","volume":"54","author":"Skipper","year":"1970","journal-title":"Cancer Chemother Rep"},{"key":"R26-20250527","first-page":"2636","article-title":"Criteria associated with destruction of leukemia and solid tumor cells in animals","volume":"27","author":"Skipper","year":"1967","journal-title":"Cancer Res"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41375-019-0422-z","article-title":"Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children\u2019s Oncology Group","volume":"33","author":"Steinherz","year":"2019","journal-title":"Leukemia"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 Methotrexate Randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","article-title":"Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"30","author":"Dunsmore","year":"2012","journal-title":"J Clin Oncol"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T20:03:51Z","timestamp":1748376231000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002999","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"2024-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}